Revolution Medicines Inc. (NASDAQ:RVMD) has a beta value of 0 and has seen 1,526,954 shares traded in the last trading session. The company, currently valued at $2.44 Billion, closed the last trade at $33.19 per share which meant it lost -$1.76 on the day or -5.04% during that session. The RVMD stock price is -69.27% off its 52-week high price of $56.18 and 38.14% above the 52-week low of $20.53. If we look at the company’s 10-day average daily trading volume, we find that it stood at 375.38 Million shares traded. The 3-month trading volume is 585.48 Million shares.
The consensus among analysts is that Revolution Medicines Inc. (RVMD) is a Buy stock at the moment, with a recommendation rating of 1.8. None of the analysts rate the stock as a Sell, while none rate it as Overweight. 1 out of 5 have rated it as a Hold, with 4 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.52.
Revolution Medicines Inc. (NASDAQ:RVMD) trade information
Despite being -5.04% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, Apr 27 when the RVMD stock price touched $43.49- or saw a rise of 23.68%. Year-to-date, Revolution Medicines Inc. shares have moved -16.17%, while the 5-day performance has seen it change -19.44%. Over the past 30 days, the shares of Revolution Medicines Inc. (NASDAQ:RVMD) have changed -24.45%. Short interest in the company has seen 6.77 Million shares shorted with days to cover at 0.01.
Wall Street analysts have a consensus price target for the stock at $51.25, which means that the shares’ value could jump 54.41% from current levels. The projected low price target is $43 while the price target rests at a high of $55. In that case, then, we find that the current price level is +65.71% off the targeted high while a plunge would see the stock lose 29.56% from current levels.
Revolution Medicines Inc. (RVMD) estimates and forecasts
Figures show that Revolution Medicines Inc. shares have underperformed across the wider relevant industry. The company’s shares have gained +4.77% over the past 6 months, with this year growth rate of -13.43%, compared to 16.6% for the industry. Other than that, the company has, however Increased its growth outlook for the 2021 fiscal year revenue. Growth estimates for the current quarter are 29.7% and -19.6% for the next quarter. Revenue growth from the last financial year stood is estimated to be -12.1%.
5 analysts offering their estimates for the company have set an average revenue estimate of $9.46 Million for the current quarter. 5 have an estimated revenue figure of $9.46 Million for the next quarter concluding in June 01, 2021. Year-ago sales stood $11.55 Million and $10.03 Million respectively for this quarter and the next, and analysts expect sales will grow by -18.1% for the current quarter and -5.6% for the next.
Earnings growth for 2021 is a modest -91.7%.
Revolution Medicines Inc. (NASDAQ:RVMD)’s Major holders
Insiders own 6.23% of the company shares, while shares held by institutions stand at 80.75% with a share float percentage of 86.11%. Investors are also buoyed by the number of investors in a company, with Revolution Medicines Inc. having a total of 180 institutions that hold shares in the company. The top two institutional holders are FMR, LLC with over 9.34 Million shares worth more than $369.75 Million. As of December 30, 2020, FMR, LLC held 12.73% of shares outstanding.
The other major institutional holder is TRV GP III, LLC, with the holding of over 7.02 Million shares as of December 30, 2020. The firm’s total holdings are worth over $278.08 Million and represent 9.57% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Fidelity Select Portfolios – Health Care. As of December 30, 2020, the former fund manager holds about 1.79% shares in the company for having 1312714 shares of worth $51.97 Million while later fund manager owns 1.28 Million shares of worth $58.47 Million as of February 27, 2021, which makes it owner of about 1.74% of company’s outstanding stock.